Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.4K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.4K
Seizures: Classification01:13

Seizures: Classification

1.8K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.8K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

829
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
829
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Widening participation in the International League Against Epilepsy: Looking to the future.

Epilepsia open·2026
Same author

Experiences and service-uptake factors of receiving and providing care for meningitis and its sequelae: a qualitative systematic review.

BMC medicine·2026
Same author

Migraine, headache disorders, and brain health: aligning advocacy with the UN Sustainable Development Goals.

The journal of headache and pain·2026
Same author

Nonsuicidal self-injurious behavior in patients with and without epilepsy: a case-control study.

Epilepsy & behavior : E&B·2026
Same author

Response to comments to "Prevalence and trajectories of post-COVID-19 neuromuscular conditions: A systematic-review and meta-analysis".

Journal of the neurological sciences·2026
Same author

Response to comments to "Prevalence and trajectories of post-COVID-19 neuromuscular conditions: A systematic-review and meta-analysis".

Journal of the neurological sciences·2026

Related Experiment Video

Updated: Feb 21, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.6K

Epilepsy, Comorbidities and Treatments.

Alla Guekht1,2

  • 1Moscow Research and Clinical Center for Neuropsychiatry.

Current Pharmaceutical Design
|October 10, 2017
PubMed
Summary

People with epilepsy (PWE) have higher rates of somatic and psychiatric conditions, including depression and dementia. Understanding shared mechanisms can lead to better treatments and prevention strategies for these epilepsy comorbidities.

Keywords:
Comorbiditiesepilepsypsychiatricrisk factorssomatictreatment.

More Related Videos

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

10.1K
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

26.4K

Related Experiment Videos

Last Updated: Feb 21, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.6K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

10.1K
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

26.4K

Area of Science:

  • Neurology
  • Psychiatry
  • Epidemiology

Background:

  • Epilepsy is frequently associated with numerous somatic and psychiatric conditions.
  • These comorbidities are more prevalent in people with epilepsy (PWE) than in the general population.
  • Bidirectional associations exist between epilepsy and conditions like depression, stroke, and dementia, suggesting shared underlying factors.

Purpose of the Study:

  • To review significant somatic and psychiatric comorbidities in epilepsy.
  • To explore the mechanisms and directionality of these associations.
  • To discuss the implications of comorbidities for epilepsy treatment and management.

Main Methods:

  • Literature review of population-based studies.
  • Analysis of medical records databases and survey data.
  • Examination of prevalence rates of comorbidities in PWE.

Main Results:

  • Population-based studies confirm a significantly higher prevalence of various medical conditions in PWE.
  • Evidence indicates a stronger association between epilepsy and comorbidities than observed in the general population.
  • Common underlying mechanisms and risk factors likely explain the bidirectional associations observed.

Conclusions:

  • Comorbidities significantly impact the disease burden and patient outcomes in epilepsy.
  • Effective management of PWE requires addressing these coexisting conditions.
  • Understanding shared pathways may reveal novel therapeutic targets and preventive strategies.